Finerenone

Among patients with type 2 diabetes and chronic kidney disease, finerenone treatment may provide cardiovascular benefits, according to data published in the Clinical Journal of the American Society of Nephrology.

As part of the 2022 Year in Review, Cardiology Today compiled a list of selected drugs and devices related to the specialty that were newly approved or cleared. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omissions. Appearance of a drug or device does not constitute any endorsement by Cardiology Today, its editors, publisher or editorial board. – The Editors

Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial outcomes in several renin-angiotensin-aldosterone system-mediated disease states.

Adults with type 2 diabetes and chronic kidney disease using the nonsteroidal mineralocorticoid receptor antagonist finerenone have lower risks for pneumonia and COVID-19, according to findings published in JAMA Network Open.

BOSTON — Finerenone reduces CV and renal events in patients with type 2 diabetes and chronic kidney disease, and albuminuria is a good screening tool to identify candidates, according to a speaker.

Bayer has received FDA approval to update to the label for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, according to a press release.

A subanalysis of the FIDELITY trial showed finerenone reduced risk for all-cause and CV mortality, including sudden cardiac death, compared with placebo in adults with type 2 diabetes and chronic kidney disease.

Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of end-stage kidney disease, according to data published in the European Heart Journal.

PHILADELPHIA — For adults with type 2 diabetes and chronic kidney disease, a novel nonsteroidal mineralocorticoid receptor antagonist can play a key role in reducing risk for serious cardiorenal outcomes, according to a speaker.

The American Diabetes Association announced updates to its 2022 Standards of Medical Care in Diabetes to reflect new data on cardiovascular outcomes with diabetes and kidney disease and use of SGLT2 inhibitors.